{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:04:03Z","timestamp":1758672243085,"version":"3.44.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.virol.2016.10.028","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T23:00:35Z","timestamp":1479164435000},"page":"247-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients"],"prefix":"10.1016","volume":"500","author":[{"given":"B\u00e9n\u00e9dicte","family":"Vanwalscappel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Rato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"Perez-Olmeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"D\u00edez Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Casartelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Alcami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Mammano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2016.10.028_bib1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/JVI.02687-13","article-title":"Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo","volume":"88","author":"Abdel-Mohsen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib2","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/molbev\/msh196","article-title":"A Robust Measure of HIV-1 Population Turnover Within Chronically Infected Individuals","volume":"21","author":"Achaz","year":"2004","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.virol.2016.10.028_bib3","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1128\/JVI.00449-14","article-title":"HIV-1 Vpu Antagonism of Tetherin Inhibits Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells","volume":"88","author":"Alvarez","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib4","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1128\/JVI.77.4.2550-2558.2003","article-title":"G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates","volume":"77","author":"Amara","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib5","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1128\/JVI.02080-10","article-title":"Differential Effects of Human Immunodeficiency Virus Type 1 Vpu on the Stability of BST-2\/Tetherin","volume":"85","author":"Andrew","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib6","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1073\/pnas.1321507111","article-title":"Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity","volume":"111","author":"Arias","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.virol.2016.10.028_bib7","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1086\/652420","article-title":"Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa\u20102a in HIV\u20101\u2013monoinfected participants: a phase II clinical trial","volume":"201","author":"Asmuth","year":"2010","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jis663","article-title":"Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration","volume":"207","author":"Azzoni","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib9","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1073\/pnas.86.13.4958","article-title":"Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon","volume":"86","author":"Bednarik","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2016.10.028_bib10","doi-asserted-by":"crossref","first-page":"e1005024","DOI":"10.1371\/journal.ppat.1005024","article-title":"Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells","volume":"11","author":"Bego","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.10.028_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.virol.2016.10.028_bib12","article-title":"Modest Attenuation of HIV-1 Vpu Alleles Derived from Elite Controller Plasma","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.virol.2016.10.028_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622314551934","article-title":"Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C","volume":"6","author":"Cortez","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.virol.2016.10.028_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-10-128","article-title":"Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice","volume":"10","author":"Dave","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2016.10.028_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2007.0076","article-title":"Interferon may prevent HIV viral rebound after HAART interruption in HIV patients","volume":"28","author":"Dianzani","year":"2008","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.virol.2016.10.028_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virol.2013.03.015","article-title":"A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2\/Tetherin and enhance viral egress","volume":"441","author":"Douglas","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.virol.2016.10.028_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1742-4690-7-114","article-title":"Modulation of HIV-1-host interaction: role of the Vpu accessory protein","volume":"7","author":"Dub\u00e9","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2016.10.028_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/infdis\/165.5.793","article-title":"Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction","volume":"165","author":"Edlin","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.7326\/0003-4819-117-6-457","article-title":"In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response","volume":"117","author":"Edlin","year":"1992","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.virol.2016.10.028_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1742-4690-10-146","article-title":"Relative resistance of HIV-1 founder viruses to control by interferon-alpha","volume":"10","author":"Fenton-May","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2016.10.028_bib21","first-page":"1025","article-title":"Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts >150 x 10(6)\/L: results of the Zidon trial","volume":"9","author":"Fern\u00e1ndez-Cruz","year":"1995","journal-title":"Zidon Study Group. AIDS"},{"key":"10.1016\/j.virol.2016.10.028_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00042560-199712010-00005","article-title":"Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197","volume":"16","author":"Fischl","year":"1997","journal-title":"J. Acquir Immune Defic. Syndr. Hum. Retrovirol"},{"key":"10.1016\/j.virol.2016.10.028_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/aid.1992.8.199","article-title":"Interferons in the persistence, pathogenesis, and treatment of HIV infection","volume":"8","author":"Francis","year":"1992","journal-title":"AIDS Res Hum. Retrovir."},{"key":"10.1016\/j.virol.2016.10.028_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/infdis\/169.6.1351","article-title":"Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection","volume":"169","author":"Frissen","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.chom.2012.10.007","article-title":"Innate Sensing of HIV-1 Assembly by TetherinInduces NFkB-Dependent Proinflammatory Responses","volume":"12","author":"Gal\u00e3o","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2016.10.028_bib26","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1128\/JVI.00854-10","article-title":"Characterization of the Alpha Interferon-Induced Postentry Block to HIV-1 Infection in Primary Human Macrophages and T Cells","volume":"84","author":"Goujon","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/aid.1987.3.125","article-title":"Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro","volume":"3","author":"Hartshorn","year":"1987","journal-title":"AIDS Res Hum. Retrovir."},{"key":"10.1016\/j.virol.2016.10.028_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/107999001753238114","article-title":"Low-Dose IFN- \u03b1Monotherapy in Treatment-Naive Individuals with HIV-1 Infection: evidence of Potent Suppression of Viral Replication","volume":"21","author":"Hatzakis","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.virol.2016.10.028_bib29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0140-6736(85)92144-0","article-title":"Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro","volume":"1","author":"Ho","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2016.10.028_bib30","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1016\/j.jmb.2013.09.029","article-title":"Emerging Role of the Host Restriction Factor Tetherin in Viral Immune Sensing","volume":"425","author":"Hotter","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2016.10.028_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/infdis\/jis211","article-title":"Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a","volume":"205","author":"Hubbard","year":"2012","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib32","first-page":"138","article-title":"A statistical test for detecting geographic subdivision","volume":"9","author":"Hudson","year":"1992","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.virol.2016.10.028_bib33","first-page":"11761","article-title":"Quantifying the Antiviral Effect of IFN on HIV-1 Replication in Cell Culture","volume":"5","author":"Ikeda","year":"2015","journal-title":"Nat. Publ. Group"},{"key":"10.1016\/j.virol.2016.10.028_bib34","doi-asserted-by":"crossref","first-page":"35060","DOI":"10.1074\/jbc.M109.058305","article-title":"HIV-1 accessory protein Vpu internalizes cell-surface BST-2\/tetherin through transmembrane interactions leading to lysosomes","volume":"284","author":"Iwabu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2016.10.028_bib35","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1128\/JVI.03472-13","article-title":"Activities of Transmitted\/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release","volume":"88","author":"Jafari","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib36","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/gkf436","article-title":"MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform","volume":"30","author":"Katoh","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2016.10.028_bib37","doi-asserted-by":"crossref","first-page":"e1004010","DOI":"10.1371\/journal.ppat.1004010","article-title":"Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy","volume":"10","author":"Kearney","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.10.028_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.virol.2007.01.022","article-title":"A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG","volume":"363","author":"Krummheuer","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.virol.2016.10.028_bib39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/171.4.822","article-title":"Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression","volume":"171","author":"K\u00fcnzi","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib40","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/JVI.03719-14","article-title":"Vpu Is the Main Determinant for Tetraspanin Downregulation in HIV-1-Infected Cells","volume":"89","author":"Lambel\u00e9","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib41","first-page":"805","article-title":"Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection","volume":"112","author":"Lane","year":"1990","journal-title":"Random., Place.-Control. Trial Ann. Intern. Med."},{"key":"10.1016\/j.virol.2016.10.028_bib42","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1074\/jbc.M114.630095","article-title":"Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly","volume":"290","author":"Lewinski","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2016.10.028_bib43","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chom.2008.04.008","article-title":"HIV-1 accessory proteins--ensuring viral survival in a hostile environment","volume":"3","author":"Malim","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2016.10.028_bib44","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/JVI.72.3.2208-2212.1998","article-title":"Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1","volume":"72","author":"Mar\u00e9chal","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jac\/dkl497","article-title":"Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV\/hepatitis C virus","volume":"59","author":"Marucco","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2016.10.028_bib46","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1128\/JVI.05788-11","article-title":"The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR","volume":"86","author":"Matusali","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib47","doi-asserted-by":"crossref","first-page":"e1003299","DOI":"10.1371\/journal.ppat.1003299","article-title":"Vpu binds directly to tetherin and displaces it from nascent virions","volume":"9","author":"McNatt","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.10.028_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.virol.2015.03.015","article-title":"Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection","volume":"482","author":"Mlcochova","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.virol.2016.10.028_bib49","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v7.i8.1133","article-title":"Antiviral therapies for chronic hepatitis C virus infection with cirrhosis","volume":"7","author":"Nakamoto","year":"2015","journal-title":"WJH"},{"key":"10.1016\/j.virol.2016.10.028_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jir.2009.0077","article-title":"Human Immunodeficiency Virus, Restriction Factors, and Interferon","volume":"29","author":"Neil","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.virol.2016.10.028_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.virol.2016.10.028_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/jac\/dku424","article-title":"Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations","volume":"70","author":"Nguyen","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.virol.2016.10.028_bib53","doi-asserted-by":"crossref","first-page":"e35411","DOI":"10.1371\/journal.pone.0035411","article-title":"Counteraction of Tetherin Antiviral Activity by Two closely related SIVs differing by the presence of a Vpu gene","volume":"7","author":"Nikovics","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.virol.2016.10.028_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-198902000-00008","article-title":"Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study","volume":"3","author":"Orholm","year":"1989","journal-title":"AIDS"},{"key":"10.1016\/j.virol.2016.10.028_bib55","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1073\/pnas.1304288110","article-title":"Phenotypic properties of transmitted founder HIV-1","volume":"110","author":"Parrish","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2016.10.028_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-11-15","article-title":"HIV Nef and Vpu protect HIV-infected CD4+T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2","volume":"11","author":"Pham","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2016.10.028_bib57","doi-asserted-by":"crossref","first-page":"e1003895","DOI":"10.1371\/journal.ppat.1003895","article-title":"Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals","volume":"10","author":"Pickering","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.10.028_bib58","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1073\/pnas.1111573109","article-title":"Role of retroviral restriction factors in the interferon-\u03b1-mediated suppression of HIV-1 in vivo","volume":"109","author":"Pillai","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.virol.2016.10.028_bib59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1126\/science.2470148","article-title":"Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines","volume":"244","author":"Poli","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.virol.2016.10.028_bib60","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/molbev\/msp077","article-title":"FastTree: computing large minimum evolution trees with profiles instead of a distance matrix","volume":"26","author":"Price","year":"2009","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.virol.2016.10.028_bib61","first-page":"2019","article-title":"Downmodulation of CCR7 by HIV-1 Vpu Results in Impaired Migration and Chemotactic Signaling within CD4","volume":"7","author":"Ramirez","year":"2014","journal-title":"CellReports"},{"key":"10.1016\/j.virol.2016.10.028_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2015.09.028","article-title":"Kinetics of the establishment of HIV-1 viral interference and comprehensive analysis of the contribution of viral genes","volume":"487","author":"Remion","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.virol.2016.10.028_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01878118","article-title":"Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals","volume":"8","author":"Rivero","year":"1994","journal-title":"Biotherapy"},{"key":"10.1016\/j.virol.2016.10.028_bib65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fmicb.2014.00177","article-title":"Mechanisms underlying HIV-1 Vpu-mediated viral egress","volume":"5","author":"Roy","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.virol.2016.10.028_bib66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jmb.2013.12.003","article-title":"Innate Antiviral Immune Signaling, Viral Evasion and Modulation by HIV-1","volume":"426","author":"Rustagi","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2016.10.028_bib67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2016.10.028_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fmicb.2014.00163","article-title":"Counteraction of the multifunctional restriction factor tetherin","volume":"5","author":"Sauter","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.virol.2016.10.028_bib69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.virol.2016.10.028_bib70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.chom.2010.10.008","article-title":"Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu","volume":"8","author":"Shah","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2016.10.028_bib71","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/infdis\/173.5.1107","article-title":"Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity","volume":"173","author":"Skillman","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.10.028_bib72","first-page":"6","article-title":"Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection","volume":"338","author":"Spanish Ribavirin","year":"1991","journal-title":"Span. Ribavirin Trial Group. Lancet"},{"key":"10.1016\/j.virol.2016.10.028_bib73","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.coviro.2013.08.004","article-title":"ScienceDirectHIV accessory proteins versus host restriction factors","volume":"3","author":"Strebel","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib74","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jir.2009.0090","article-title":"Interferon-\u03b1 Produces Significant Decreases in HIV Load","volume":"30","author":"Tavel","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.virol.2016.10.028_bib75","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.02272-12","article-title":"Stimulation of NF- B Activity by the HIV Restriction Factor BST2","volume":"87","author":"Tokarev","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","article-title":"The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein","volume":"3","author":"Van Damme","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2016.10.028_bib77","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1128\/JVI.00611-15","article-title":"HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4 +T Lymphocytes","volume":"89","author":"Vassena","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib78","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.1128\/JVI.01235-09","article-title":"Partial Inhibition of Human Immunodeficiency Virus Replication by Type I Interferons: Impact of Cell-to-Cell Viral Transfer","volume":"83","author":"Vendrame","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.10.028_bib79","doi-asserted-by":"crossref","first-page":"e1003483","DOI":"10.1371\/journal.ppat.1003483","article-title":"Mechanism of HIV-1 Virion Entrapment by Tetherin","volume":"9","author":"Venkatesh","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.10.028_bib80","doi-asserted-by":"crossref","first-page":"e59283","DOI":"10.1371\/journal.pone.0059283","article-title":"Genetic characterization of natural variants of Vpu from HIV-1 infected individuals from Northern India and their impact on virus release and cell death","volume":"8","author":"Verma","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.virol.2016.10.028_bib81","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1128\/jvi.66.12.7193-7200.1992","article-title":"Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4","volume":"66","author":"Willey","year":"1992","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.virol.2016.10.028_bib82","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/aid.1988.4.287","article-title":"Inhibition of growth of HIV by human natural interferon in vitro","author":"Yamada","year":"1988","journal-title":"AIDS Res. Hum. Retrovir."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216303361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216303361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:50Z","timestamp":1758587990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682216303361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":82,"alternative-id":["S0042682216303361"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2016.10.028","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2016.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}